J&J un­veils PhI­Ia da­ta of oral an­tivi­ral for dengue fever pre­ven­tion

John­son & John­son’s oral an­tivi­ral has shown hints of ac­tiv­i­ty in a Phase IIa hu­man chal­lenge tri­al for the pre­ven­tion of mos­qui­to-borne dis­ease dengue fever …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER